Biological subtypes of breast cancer: Prognostic and therapeutic implications.
By O. Yersal, S. Barutça. World Journal of Clinical Oncology, 2014
1,078 citations recorded by the source corpus.
Breast cancer is a heterogeneous complex of diseases, a spectrum of many subtypes with distinct biological features that lead to differences in response patterns to various treatment modalities and clinical outcomes. Traditional classification systems regarding biological characteristics may have limitations for patient-tailored treatment strategies. Tumors with similar clinical and pathological presentations may have different behaviors. Analyses of breast cancer with new molecular techniques now hold promise for the development of more accurate tests for the prediction of recurrence. Gene signatures have been developed as predictors of response to therapy and protein gene products that have direct roles in driving the biology and clinical behavior of cancer cells are potential targets for the development of novel therapeutics. The present review summarizes current knowledge in breast cancer molecular biology, focusing on novel prognostic and predictive factors.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/9ed5cc8a74c80d5feeff9eefd9a8ed0ddb084580
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Shuroug A. Alowais
- S. Alghamdi
- N. Alsuhebany
- Abdulrahman I. Alshaya
- Sumaya N Almohareb
- H. Badreldin
- Majed S. Al Yami
- O. Kondrashova
Citations in the corpus
- Revolutionizing healthcare: the role of artificial intelligence in clinical practice (2023, background): “Such molecular classifications, first developed for breast cancer and later extended to other cancers like colorectal, ovarian, and sarcomas, hold substantial implications for diagnosis, prognosis, and treatment selection [38, 39].”
- Deep learning in cancer diagnosis, prognosis and treatment selection (2021, background): “Molecular subtypes were first described for breast cancer [85, 86], then later for other cancers including colorectal”